Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company, is looking to change how cystoscopies for bladder cancer are performed with the goal of potentially lowering recurrence rates and ultimately helping improve patients’ lives and long-term outlook. “The company’s i/Blue Imaging System(TM) is a breakthrough cancer visualization technology currently in the manufacturing stage with Lighthouse Imaging, an FDA registered and ISO 13485:2016 certified contract manufacturer located in Maine. The project is on track for completion in 2022,” reads a recent article on the innovative solution. “Imagin Medical’s i/Blue Imaging System has the potential to revolutionize current cystoscopies by showing both white light and blue light images simultaneously side-by-side on the screen in real time, providing clear visualization of the fluoresced flat cancer cells and margins in context within the bladder. This capability eliminates surgeons’ need to change between images and can potentially lead to lower recurrence rates and help assure a better standard of care and future for bladder cancer patients. In addition, the i/Blue System will come at an overall lower system cost and, because it will adapt to most endoscopes on the market, will allow hospitals and doctor’s offices to make use of scopes they already own, adding to the savings.”
To view the full article, visit https://ibn.fm/RHuH7
About Imagin Medical
Imagin Medical is a surgical imaging company focused on advancing new methods of visualizing cancer during minimally invasive procedures. The company believes its first product, the i/Blue Imaging System, with its proprietary optics and light sensors, will greatly increase the efficiency and accuracy of detecting cancer for removal, helping to reduce recurrence rates. The company’s initial focus is bladder cancer. For more information about the company, visit www.ImaginMedical.com.
NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at https://ibn.fm/IMEXF
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork